aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Insilico Medicine is a global AI biotechnology firm dedicated to extending human productive longevity. Headquartered in Hong Kong, with R&D and management resources across the USA, Belgium, Russia, UK, Taiwan, and China, the company leverages AI to develop innovative solutions in drug discovery and development. Key products include the PHARMA.AI suite, PandaOmics, Generative Biologics, Chemistry42, and inClinico.
Insilico Medicine has achieved significant milestones in AI-driven drug discovery, partnering with leading pharmaceutical companies and research institutions. The company has been recognized for its pioneering work in integrating AI with biotechnology, contributing to advancements in healthcare and longevity. Notable figures in the organization include its founder and CEO, Alex Zhavoronkov, and a distinguished scientific advisory board.
Operating Status
Active
Ownership Type(s)
Venture Capital
Main Product(s)
Drug Discovery
Technology
AI, Machine Learning
Tags
Biotech, Ai Operations
Model Types
Platform, Software
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Insilico Medicine founded?
Insilico Medicine was founded in 2014.
Where is Insilico Medicine’s headquarters located?
Insilico Medicine’s headquarters is located in Kong'an, HB, CN.
When was Insilico Medicine’s last funding round?
Insilico Medicine’s most recent funding round was for $35M (USD) in August 2022.
How many employees does Insilico Medicine have?
Insilico Medicine has 278 employees as of Feb 4, 2024.
How much has Insilico Medicine raised to-date?
As of July 05, 2023, Insilico Medicine has raised a total of $401.3M (USD) since Aug 10, 2022.
Add Comparison
Total Raised to Date
$401.3M
USD
Last Update Aug 10, 2022
Last Deal Details
$35M
USD
Aug 10, 2022
Series D
Total Employees Over Time
278
As of Feb 2024
Insilico Medicine Address
Kong'an,
Hubei
People's Republic of China
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts